Medical University Innsbruck
Innsbruck, Tyrol, 6020, Austria
Location status: Recruiting
NCT Number: NCT07442929
Different mixtures of local anesthetics or local anesthetics with adjuvants that are known to precipitate in vitro are tested in human cerebrospinal fluid (CSF). CSF is gained from patients with normal pressure hydrocephalus scheduled for elective lumbar puncture. Patients signed an ICF for leftover samples.
CSF will be assessed for pH values at different timepoints (t0-t3; 0 to 60 minutes).
In a second step six commonly used mixtures of LA with LA or LAs with adjuvants will be mixed using the following mixture ratios: ropivacaine 0.75% + lidocaine 2% (ratio 1:1), ropivacaine 0,75% + mepivacaine 2% (ratio 1:1), ropivacaine 0.75% + chloroprocaine 2% (ratio 1:1), lidocaine 2% + sodium bicarbonate 8.4% (ratio 1:0.1), ropivacaine 0.75% + lidocaine 2% + sodium bicarbonate 8.4% (ratio 1:1:0.1) and ropivacaine 0.75% + dexamethasone (1.5:1). The used mixture ratios are inspired by commonly mixtures described in the current literature and have been proven to precipitate in vitro. For every mixture, a Grade of Crystallisation will be determined at baseline without CSF and then at t0 (immediately) to t3 (60 minutes) every 15 minutes.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Innsbruck, Tyrol, 6020, Austria
Location status: Recruiting
Different mixtures of local anesthetics or local anesthetics with adjuvants that are known to precipitate in vitro are tested in human cerebrospinal fluid (CSF). CSF is gained from patients with normal pressure hydrocephalus scheduled for elective lumbar puncture. Patients signed an ICF for leftover samples.
CSF will be assessed for pH values at different timepoints (t0-t3; 0 to 60 minutes).
In a second step six commonly used mixtures of LA with LA or LAs with adjuvants will be mixed using the following mixture ratios: ropivacaine 0.75% + lidocaine 2% (ratio 1:1), ropivacaine 0,75% + mepivacaine 2% (ratio 1:1), ropivacaine 0.75% + chloroprocaine 2% (ratio 1:1), lidocaine 2% + sodium bicarbonate 8.4% (ratio 1:0.1), ropivacaine 0.75% + lidocaine 2% + sodium bicarbonate 8.4% (ratio 1:1:0.1) and ropivacaine 0.75% + dexamethasone (1.5:1). The used mixture ratios are inspired by commonly mixtures described in the current literature and have been proven to precipitate in vitro. For every mixture, a Grade of Crystallisation will be determined at baseline without CSF and then at t0 (immediately) to t3 (60 minutes) every 15 minutes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 1 hour
For the grading of detectable precipitations, a scale from 0 (no signs of precipitation / single particulates < 10 μm) to 5 (heavy polymorphic crystallization: > 100 solid bodies > 10 μm, and > 1 solid body > 50 μm or > 1 solid body > 100 μm) will be used.
Time frame: 1 hour
pH value
Time frame: 1 hour
pCO2 in mmHg
Contact information is provided by the study sponsor or research team.
Elisabeth Gasteiger, MD PhD
CONTACT
Lukas Gasteiger, MD PD
CONTACT
Medical University Innsbruck
Other
Crystallization of Local Anesthetic and Adjuvant Mixtures in Cerebrospinal Fluid as a Model for Interstitial Space - a Semiquantitative in Vitro Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07050628
Brain Diseases, Central Nervous System Diseases
Chicago, Illinois, United States
View Trial DetailsNCT06253858
Brain Diseases, Central Nervous System Diseases
Hershey, Pennsylvania, United States
View Trial DetailsNCT05910944
Brain Diseases, Central Nervous System Diseases
Kuopio, Finland
View Trial DetailsNCT06724029
Aneurysm, Aneurysms
Bergamo, BG, Italy
View Trial Details